TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04868604: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Sponsor: Clarity Pharmaceuticals Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,295,910

Rescue Site Savings

+$863,940

Unlock Full NCT04868604 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04868604 Rescue Dossier →